Kirbakaran Munuswamy, MD
Cardiovascular Disease · Fort Lauderdale, FLNPI 1447228101
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,023 of the $51,105 with a category attached, or 90.1%. Amgen accounts for 61.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $15,839 and has fallen 99.8% since, to $35 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $491.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$31K
- Astellas Pharma US Inc$18K
- Alnylam Pharmaceuticals Inc.$429
- Boston Scientific$428
- Biotronik Inc.$275
- Edwards Lifesciences$177
- plus $848 from 14 others
Across 12 payments — averaging $6713.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$75K
- Amgen$5K
- Boehringer Ingelheim International GmbH$85
What the payments were for
- Speaking & faculty fees$46,02390%
- Travel & lodging$1,4013%
- Food & beverage$3,5837%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 37 | $31,346 |
| Astellas Pharma US Inc | 15 | $17,601 |
| Alnylam Pharmaceuticals Inc. | 7 | $429 |
| Boston Scientific | 6 | $428 |
| Biotronik Inc. | 2 | $275 |
| Edwards Lifesciences | 2 | $177 |
| Abbott | 3 | $164 |
| Johnson & Johnson | 7 | $118 |
| Pfizer | 3 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $97 |
| Cardiovascular Systems Inc. | 1 | $94 |
| Novartis | 3 | $63 |
| Heartflow, Inc. | 1 | $32 |
| AstraZeneca | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Agepha Pharma FZ LLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$31,147
- ONPATTRO$330
- Watchman$232
- Edwards SAPIEN 3 Transcatheter Heart Valve$125
- LUX-Dx Insertable Cardiac Monitor$120
- HeartMate$117
How this compares
$51,105 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 344 | $374,041 |
| Repatha SureclickEvolocumab | 109 | $88,444 |
| EntrestoSacubitril/Valsartan | 82 | $88,125 |
| XareltoRivaroxaban | 62 | $62,169 |
| VascepaIcosapent Ethyl | 26 | $17,760 |
| Praluent PenAlirocumab | 16 | $12,100 |
| NexlizetBempedoic Acid/Ezetimibe | 22 | $11,965 |
| Repatha SyringeEvolocumab | 11 | $11,486 |
| Ezetimibe | 304 | $6,911 |
| Rosuvastatin Calcium | 357 | $4,725 |
| Atorvastatin Calcium | 466 | $4,672 |
| Metoprolol Succinate | 285 | $3,651 |
| Valsartan | 102 | $2,380 |
| Amlodipine Besylate | 280 | $2,259 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 44 | $1,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $116 | $374,041344 claims |
| NovartisEntresto | $63 | $88,12582 claims |
| Johnson & JohnsonXarelto | $118 | $62,16962 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Fort Lauderdale
- David PerloffFort Lauderdale$384K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.